Tecentriq (atezolizumab) / Roche - LARVOL DELTA

Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy. (PubMed, Transl Lung Cancer Res) - "Chemoimmunotherapy combining platinum-based chemotherapy and etoposide with an anti-programmed death-ligand 1 (PD-L1) antibody is the standard treatment for patients with extensive-stage small cell lung cancer (ES-SCLC)...The platinum-based chemotherapy regimens included atezolizumab in 67.3% of cases and durvalumab in 32.8%, respectively...Liver metastasis is a significant predictor of outcomes after chemoimmunotherapy in patients with ES-SCLC. The maximal diameter and number of liver metastases may affect the immune response in patients with liver metastasis."

Biomarker • IO biomarker • Journal • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • GRP-10

EFFICACY AND OUTCOMES OF NOVEL THERAPEUTIC AGENTS AS MONOTHERAPY OR IN COMBINATION WITH CONVENTIONAL THERAPY IN MYELODYSPLASTIC SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS (EHA 2025) - "Newer agents included Rigosertib (41%, n=312/770), Imetelstat (15%, n=118/770), Pembrolizumab (8%, n=65/770), Enasidenib (9%, n=67/770), and Sabatolimab (7%, n=53/770) Ivosidenib (6%, 45/770), Elritercept 2%, n=15 /770), Pevonedistat (3%, 21/770), Emavusertib (2%, 15/770), Atezolizumab (6%, 46/770), and Olutasidenib (2%, n=13/770). The most commonly used conventional agent was azacitidine (19%, n= 147/770)... This study highlights promising results with the investigational agents for MDS. However, large studies with more power are needed to strengthen our understanding of these investigational agents in MDS patients."

Combination therapy • Monotherapy • Retrospective data • Review • Anemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Neutropenia • Oncology • Thrombocytopenia

EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS OF RICHTER TRANSFORMATION: A SINGLE CENTER EXPERIENCE OF THE LAST 20 YEARS (EHA 2025) - "CIT included fludarabine + cyclophosphamide + rituximab (FCR) and bendamustine + rituximab (BR) regimens; TT included Bruton tyrosine kinase inhibitors (BTKi), Bcl-2 and phosphatidylinositol 3-kinase inhibitors...First line treatment for RT included: CHOP-like regimens in 41 pts (76%), radiotherapy alone in 2 pts (4%) with very localized disease, ABVD regimen in 3 pts (5%), chemofree regimen (obinutuzumab, atezolizumab, venetoclax) in 2 pts (4%) and palliative care in 4 pts (7%); 2 pts (4%) died before treatment... Over the past five years, we have observed an increased frequency of RT. This observation may be related to the longer survival in pts with unfavorable molecular characteristics when treated with TT. Our results confirmed the relatively favorable outcomes in pts who have never previously received treatment for CLL and who lack TP53 aberrations."

Clinical • B Cell Lymphoma • Bone Marrow Transplantation • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Hodgkin Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Palliative care • Richter's Syndrome • BCL2 • TP53

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: Ronald Buckanovich | Trial completion date: Apr 2028 ➔ Mar 2033 | Trial primary completion date: Apr 2028 ➔ Mar 2031

Platinum resistant • Trial completion date • Trial primary completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • BRCA • CD4

Clinical insights: atezolizumab-induced myositis mimicking hepatic injury. (PubMed, BMJ Case Rep) - "The patient was managed successfully and has an ongoing response more than 6 months after stopping immunotherapy and 18 months since initial diagnosis. This case report aims to address the knowledge gap regarding this irAE with insights on diagnosis and management."

Journal • Hepatology • Immunology • Liver Failure • Lung Cancer • Musculoskeletal Diseases • Myositis • Oncology • Rheumatology • Small Cell Lung Cancer • Solid Tumor

Simultaneous Determination of Atezolizumab and Bevacizumab by LC-MS/MS in Rat Plasma and Its Application to a Pharmacokinetic Study. (PubMed, Biomed Chromatogr) - "The internal standard, abciximab, used the peptide VQWLQAGK with parent and daughter ions at m/z 471.26 and 590.32, respectively. Matrix effects at low and high QC levels confirmed consistency, with accuracy and precision for atezolizumab and bevacizumab exceeding ICH guidelines. This optimized method offers a valuable tool for pharmacokinetic profiling of atezolizumab and bevacizumab in rat plasma, providing insights for therapeutic monitoring and drug development."

Journal • PK/PD data • Preclinical

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (clinicaltrials.gov) - P1 | N=13 | Terminated | Sponsor: The Methodist Hospital Research Institute | Suspended ➔ Terminated; Poor accrual

Trial termination • Gene Therapies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • PD-L1

NeoACTIVATE: Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma (clinicaltrials.gov) - P2 | N=59 | Active, not recruiting | Sponsor: Mayo Clinic | Trial completion date: Jun 2025 ➔ Nov 2027 | Trial primary completion date: Jun 2025 ➔ Nov 2027

Trial completion date • Trial primary completion date • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor • BRAF

Incidence of thromboembolic and bleeding events in a cohort of patients with unresectable HCC on systemic therapy (ISTH 2025) - "Atezolizumab/Bevacizumab is established as a first-line systemic therapy for HCC [2]; however, concerns regarding the associated risks of bleeding and thrombosis, particularly with VEGF inhibitors, remain prevalent [3,4]. Cox regression analysis found no significant risk factors for bleeding; however, BMI and hemoglobin levels were initially predictive of thrombotic risk but lost significance in multivariate analysis. Table or Figure Upload"

Clinical • Atrial Fibrillation • Cardiovascular • Hepatocellular Cancer • Hepatology • Oncology • Portal Hypertension • Pulmonary Embolism • Respiratory Diseases • Solid Tumor

Thrombotic Thrombocytopenic Purpura (TTP) Associated with Immune Checkpoint Inhibitors: A Decade-Long Pharmacovigilance Analysis Using the FAERS Database (ISTH 2025) - "The analysis focused on commonly used ICIs, including anti-PD-1 agents (nivolumab, pembrolizumab), anti-PD-L1 agents (atezolizumab, avelumab, durvalumab), and the anti-CTLA-4 agent ipilimumab. Pembrolizumab demonstrated the highest signal strength and was associated with the greatest incidence of TTP-related complications and mortality. Table or Figure Upload"

Adverse events • Checkpoint inhibition • Oncology • Thrombocytopenic Purpura • ROR1

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: EMD Serono Research & Development Institute, Inc. | N=54 ➔ 0 | Trial completion date: Oct 2027 ➔ May 2025 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Oct 2027 ➔ May 2025

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Oncology • Solid Tumor

TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC) (ESMO-GI 2025) - No abstract available

Clinical • Late-breaking abstract • P3 data • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy (ESMO-GI 2025) - No abstract available

Clinical • Metastases • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology

Early Bevacizumab Discontinuation (EBD) Does Not Impact Outcomes in Patients with Advanced Hepatocellular Carcinoma (HCC) Treated with Atezolizumab-Bevacizumab (AB) (ESMO-GI 2025) - No abstract available

Clinical • Metastases • Hepatocellular Cancer • Oncology • Solid Tumor

Atezolizumab plus bevacizumab as first-line therapy in unresectable HCC: final analysis from phase IIIb AMETHISTA study (ESMO-GI 2025) - No abstract available

Clinical • P3 data • Hepatocellular Cancer

Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (ESMO-GI 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study. (ESMO-GI 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Comparative Effectiveness of Atezolizumab plus Bevacizumab versus Tremelimumab plus Durvalumab in a Real-World Setting (ESMO-GI 2025) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Gastrointestinal Cancer

Are clinical factors useful for identifying primary progressors (PP) in patients (pts) with hepatocellular carcinoma (HCC) undergoing first-line treatment with atezolizumab plus bevacizumab (AB)? Analysis from the Italian ARTE database (ESMO-GI 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Matching-adjusted indirect comparisons (MAICs) of nivolumab + ipilimumab (N + I) vs durvalumab + tremelimumab (D + T) and atezolizumab + bevacizumab (A + B) for first-line (1L) unresectable hepatocellular carcinoma (uHCC) (ESMO-GI 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Increase in LAG3-Positive CD8+ T cells after atezolizumab plus bevacizumab therapy as a predictor of progression-free survival in unresectable hepatocellular carcinoma (ESMO-GI 2025) - No abstract available

Hepatocellular Cancer • Oncology • Solid Tumor • CD8 • LAG3

MORPHEUS-Liver: A Phase Ib/II, randomised study evaluating tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients (pts) with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC) (ESMO-GI 2025) - No abstract available

Clinical • Combination therapy • Metastases • P1/2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Real-world outcomes for unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab plus bevacizumab (A+B) in the United States (US) (ESMO-GI 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Hepatocellular Cancer • Oncology • Solid Tumor

DKN-01 and atezolizumab as second or third-line therapy in advanced mismatch repair proficient (MMRp) oesophagogastric adenocarcinoma (OGA): WAKING trial (ESMO-GI 2025) - No abstract available

Metastases • Mismatch repair • pMMR • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Efficacy and Safety of Atezolizumab plus Bevacizumab Combined with Transcatheter Arterial Embolization and Hepatic Arterial Infusion Chemotherapy in Large Unresectable Hepatocellular Carcinoma (ESMO-GI 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor